Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


17.10.2022

1 Ann Intern Med
1 Arch Virol
3 BMJ
2 Clin Infect Dis
1 J Immunol
1 J Infect
3 J Infect Dis
1 J Pediatr
2 JAMA
1 N Engl J Med
1 Nat Med
1 Pediatr Infect Dis J
2 Pediatrics
2 PLoS Comput Biol
11 PLoS One
20 Vaccine
1 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. IOANNOU GN, Bohnert ASB, O'Hare AM, Boyko EJ, et al
    Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ann Intern Med. 2022 Oct 11. doi: 10.7326/M22-1856.
    PubMed         Abstract available


    Arch Virol

  2. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    PubMed         Abstract available


    BMJ

  3. MAHASE E
    Covid-19: Booster vaccines rolled out as hospital admissions rise.
    BMJ. 2022;379:o2484.
    PubMed        

  4. HOTEZ PJ, Matshaba M
    Promise of new malaria vaccines.
    BMJ. 2022;379:o2462.
    PubMed        

  5. ADAMS K, Rhoads JP, Surie D, Gaglani M, et al
    Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.
    BMJ. 2022;379:e072065.
    PubMed         Abstract available


    Clin Infect Dis

  6. MALOSH RE, McGovern I, Monto AS
    Influenza During the 2010-2020 Decade in the United States: Seasonal Outbreaks and Vaccine Interventions.
    Clin Infect Dis. 2022 Oct 11. pii: 6758391. doi: 10.1093.
    PubMed         Abstract available

  7. HEATH PT, Galiza EP, Baxter DN, Boffito M, et al
    Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
    Clin Infect Dis. 2022 Oct 10. pii: 6754597. doi: 10.1093.
    PubMed         Abstract available


    J Immunol

  8. MISE-OMATA S, Ikeda M, Takeshita M, Uwamino Y, et al
    Memory B Cells and Memory T Cells Induced by SARS-CoV-2 Booster Vaccination or Infection Show Different Dynamics and Responsiveness to the Omicron Variant.
    J Immunol. 2022 Oct 14. pii: jimmunol.2200525. doi: 10.4049/jimmunol.2200525.
    PubMed         Abstract available


    J Infect

  9. LEE J, Park S, Kim JY, Lim SY, et al
    No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
    J Infect. 2022 Oct 9. pii: S0163-4453(22)00600.
    PubMed        


    J Infect Dis

  10. SHOVER CL, Rosen A, Mata J, Robie B, et al
    Engaging Same-Day Peer Ambassadors to Increase Coronavirus Disease 2019 Vaccination Among People Experiencing Unsheltered Homelessness in Los Angeles County: A Hybrid Feasibility-Evaluation Study.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  11. GIBSON C, Schumann C, Neuschel K, McBride JA, et al
    COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
    J Infect Dis. 2022;226.
    PubMed         Abstract available

  12. RUDMANN KC, Brown NE, Rubis AB, Burns M, et al
    Invasive Meningococcal Disease Among People Experiencing Homelessness-United States, 2016-2019.
    J Infect Dis. 2022;226.
    PubMed         Abstract available


    J Pediatr

  13. LONG SS
    50 Years Ago in TheJournalofPediatrics: Susceptibility to Haemophilus influenzae Type b: Lessons from the Past, for the Future.
    J Pediatr. 2022;249:74.
    PubMed        


    JAMA

  14. LARKIN HD
    Progress on Replication-Defective Live Virus Vaccines.
    JAMA. 2022;328:1387.
    PubMed        

  15. KUEHN BM
    Catch-up Vaccinations Needed for Some Adolescents.
    JAMA. 2022;328:1389-1390.
    PubMed        


    N Engl J Med

  16. RUBIN EJ, Baden LR, Neuzil KM, Morrissey S, et al
    Audio Interview: Developing New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e44.
    PubMed        


    Nat Med

  17. MENTZER AJ, O'Connor D, Bibi S, Chelysheva I, et al
    Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02078.
    PubMed         Abstract available


    Pediatr Infect Dis J

  18. AIZAWA Y, Takanashi S, Ogimi C
    Updates on Coronavirus Disease 2019 in Children in Japan.
    Pediatr Infect Dis J. 2022;41:e461-e467.
    PubMed         Abstract available


    Pediatrics

  19. ESSINK BJ, Heeringa M, Jeanfreau RJ, Finn D, et al
    Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
    Pediatrics. 2022 Oct 10. pii: 189691. doi: 10.1542/peds.2022-057509.
    PubMed         Abstract available

  20. NAYAK JL, Caserta MT
    Cell-Culture-Based Influenza Vaccines: Don't Put All of Your Influenza Vaccines in the Egg Basket.
    Pediatrics. 2022 Oct 10. pii: 189690. doi: 10.1542/peds.2022-058143.
    PubMed        


    PLoS Comput Biol

  21. ALVAREZ-ZUZEK LG, Zipfel CM, Bansal S
    Spatial clustering in vaccination hesitancy: The role of social influence and social selection.
    PLoS Comput Biol. 2022;18:e1010437.
    PubMed         Abstract available

  22. WANG E, Chakraborty AK
    Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants.
    PLoS Comput Biol. 2022;18:e1010563.
    PubMed         Abstract available


    PLoS One

  23. PETROVIC V, Ristic M, Milosavljevic B, Djilas M, et al
    Pneumococcal carriage in adults aged 50 years and older in outpatient health care facility during pandemic COVID-19 in Novi Sad, Serbia.
    PLoS One. 2022;17:e0274674.
    PubMed         Abstract available

  24. HANDAYANI S, Rias YA, Kurniasari MD, Agustin R, et al
    Relationship of spirituality, health engagement, health belief and attitudes toward acceptance and willingness to pay for a COVID-19 vaccine.
    PLoS One. 2022;17:e0274972.
    PubMed         Abstract available

  25. BIKAAKO W, Kabahango P, Mugabi K, Yawe A, et al
    Breaking institutional barriers to enhance women's participation in and benefit from the Peste des Petits Ruminants and Newcastle Disease vaccine value chains for Sembabule district of Uganda.
    PLoS One. 2022;17:e0270518.
    PubMed         Abstract available

  26. JEEWANDARA C, Aberathna IS, Dayarathna S, Nimasha T, et al
    Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection.
    PLoS One. 2022;17:e0274845.
    PubMed         Abstract available

  27. STREETER AJ, Rodgers LR, Masoli J, Lin NX, et al
    Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink.
    PLoS One. 2022;17:e0275642.
    PubMed         Abstract available

  28. WANG B, Wu L, Hong X, Han Y, et al
    Risk perception and subsidy policy-based voluntary vaccination driven by multiple information sources.
    PLoS One. 2022;17:e0276177.
    PubMed         Abstract available

  29. SULIS G, Rodrigue V, Wolfson C, McMillan JM, et al
    Pneumococcal vaccination uptake and missed opportunities for vaccination among Canadian adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging (CLSA).
    PLoS One. 2022;17:e0275923.
    PubMed         Abstract available

  30. KAPAR B, Buigut S, Rana F
    Winners and losers from Pfizer and Biontech's vaccine announcement: Evidence from S&P 500 (Sub)sector indices.
    PLoS One. 2022;17:e0275773.
    PubMed         Abstract available

  31. PAUDEL YR, Du C, MacDonald SE
    The influence of place on COVID-19 vaccine coverage in Alberta: A multilevel analysis.
    PLoS One. 2022;17:e0276160.
    PubMed         Abstract available

  32. SALMON DA, Schuh HB, Sargent RH, Konja A, et al
    Impact of vaccine pause due to Thrombosis with thrombocytopenia syndrome (TTS) following vaccination with the Ad26.COV2.S vaccine manufactured by Janssen/Johnson & Johnson on vaccine hesitancy and acceptance among the unvaccinated population.
    PLoS One. 2022;17:e0274443.
    PubMed         Abstract available

  33. BAEK K, Maharjan S, Akauliya M, Thapa B, et al
    Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model.
    PLoS One. 2022;17:e0275722.
    PubMed         Abstract available


    Vaccine

  34. WHALEY M, Axon DR
    Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting.
    Vaccine. 2022 Oct 10. pii: S0264-410X(22)01229.
    PubMed         Abstract available

  35. BUDDY CREECH C, Jimenez-Truque N, Kown N, Sokolow K, et al
    Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01196.
    PubMed         Abstract available

  36. VOGELSANG EM, Polonijo AN
    Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01183.
    PubMed         Abstract available

  37. BYRNE A, Thompson LA, Filipp SL, Ryan K, et al
    COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01221.
    PubMed         Abstract available

  38. RUGHINIS C, Vulpe SN, Flaherty MG, Vasile S, et al
    Shades of doubt: Measuring and classifying vaccination confidence in Europe.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01147.
    PubMed         Abstract available

  39. CHEN JY, Hsieh SM, Hwang SJ, Liu CS, et al
    Immunogenicity and safety of high-dose quadrivalent influenza vaccine in older adults in Taiwan: A phase III, randomized, multi-center study.
    Vaccine. 2022 Oct 7. pii: S0264-410X(22)01200.
    PubMed         Abstract available

  40. CHONG CY, Tan NW, Yung CF, Li J, et al
    Effectiveness of maternal pertussis vaccination in Singapore: A test-negative case-control study.
    Vaccine. 2022 Oct 8. pii: S0264-410X(22)01219.
    PubMed         Abstract available

  41. AL-SHAIKH A, Mahmoud RI, Boukerdenna H, Muthu N, et al
    Counselling of non-communicable diseases' patients for COVID-19 vaccine uptake in Jordan: Evaluating the intervention.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01214.
    PubMed         Abstract available

  42. VAN EWIJK CE, Hazelhorst EI, Hahne SJM, Knol MJ, et al
    COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign.
    Vaccine. 2022 Oct 4. pii: S0264-410X(22)01213.
    PubMed         Abstract available

  43. SPETZ M, Lundberg L, Nwaru C, Li H, et al
    An intersectional analysis of sociodemographic disparities in Covid-19 vaccination: A nationwide register-based study in Sweden.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01186.
    PubMed         Abstract available

  44. HATHAWAY CA, Siegel EM, Gonzalez BD, Oswald LB, et al
    Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01184.
    PubMed         Abstract available

  45. MARLOWE E, Pranikoff S, Borsheim B, Salafian K, et al
    Pilot study to determine effect of an altruism intervention focusing on herd immunity to enhance influenza vaccination rates.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01194.
    PubMed         Abstract available

  46. KRAAY ANM, Steele MK, Baker JM, Hall EW, et al
    Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01193.
    PubMed         Abstract available

  47. MOHAMMED AH, Hassan BAR, Wayyes AM, Gadhban AQ, et al
    Parental health beliefs, intention, and strategies about covid-19 vaccine for their children: A cross-sectional analysis from five Arab countries in the Middle East.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01161.
    PubMed         Abstract available

  48. CHUGHTAI AA, Mohammed S, Al Ariqi L, McCarron M, et al
    Development of a road map to scale up the uptake and utilization of influenza vaccine in 22 countries of Eastern Mediterranean Region.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01159.
    PubMed         Abstract available

  49. PAGUIO JA, Ojikutu BO, Alfonso PG, Yao JS, et al
    Association of culturally competent care with influenza vaccination coverage in the United States.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01065.
    PubMed         Abstract available

  50. SIMON JK, Kennedy SB, Mahon BE, Dubey SA, et al
    Immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
    Vaccine. 2022 Oct 5. pii: S0264-410X(22)01145.
    PubMed         Abstract available

  51. MARCHESE AM, Beyhaghi H, Orenstein WA
    With established safe and effective use, protein vaccines offer another choice against COVID-19.
    Vaccine. 2022 Sep 28. pii: S0264-410X(22)01185.
    PubMed        

  52. WOLF AS, Mitsi E, Jones S, Jochems SP, et al
    Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
    Vaccine. 2022 Oct 6. pii: S0264-410X(22)01190.
    PubMed         Abstract available

  53. FERREIRA LS, de Almeida GB, Borges ME, Simon LM, et al
    Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Vaccine. 2022 Oct 3. pii: S0264-410X(22)01216.
    PubMed         Abstract available


    Virus Res

  54. HASSNINE AA, Saber MA, Fouad YM, Sarhan H, et al
    Clinical study on the efficacy of hepatitis B vaccination in hepatitis C virus related chronic liver diseases in Egypt.
    Virus Res. 2022 Oct 6:198953. doi: 10.1016/j.virusres.2022.198953.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: